Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection

STATEN ISLAND, N.Y., Oct. 2, 2023. Acurx Pharmaceuticals, Inc. ( " Acurx " or the " Company " ), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials